Publications by authors named "Daniel Figdore"
Background: Tau phosphorylated at threonine 217 (pTau217) is one of the most promising blood-based biomarkers of Alzheimer's disease (AD). This study compares the performance of two plasma pTau217 immunoassays on the Simoa platform for detection of abnormal amyloid-PET.
Method: Plasma samples from 112 individuals without cognitive impairment and 114 with mild cognitive impairment (MCI) or AD related dementia were evaluated.
Introduction: We aimed to evaluate clinical interpretation cutpoints for two plasma phosphorylated tau (p-tau)217 assays (ALZpath and Lumipulse) as predictors of amyloid status for implementation in clinical practice.
Methods: Clinical performance of plasma p-tau217 against amyloid positron emission tomography status was evaluated in participants with mild cognitive impairment or mild dementia (n = 427).
Results: Using a one-cutpoint approach (negative/positive), neither assay achieved ≥ 90% in both sensitivity and specificity.
Background: Neurofilament Light Chain (NfL) is an emerging blood biomarker of neuro-axonal injury and neurodegeneration with the potential to be used in the clinical management of various neurological conditions. Various NfL immunoassays are in development on high-throughput automated systems, but little information is available related to the comparability between assays. In this study, we performed a head-to-head comparison of four NfL immunoassays using plasma samples from individuals with various neurological conditions.
View Article and Find Full Text PDFArticle Synopsis
- - The study compared the effectiveness of Lumipulse plasma beta-amyloid (Aβ) 42/40 and pTau181 assays to detect abnormal amyloid-PET imaging in individuals with different cognitive states, using samples from 215 participants.
- - Lumipulse and IP-MS Aβ42/40 assays had the best diagnostic accuracy (AUCs of 0.81 and 0.84), while the Simoa Aβ42/40 assay showed the lowest accuracy (AUC of 0.57); combining Aβ42/40 with pTau181 provided no significant performance improvements.
- - Overall, Lumipulse Aβ42/40 and IP-MS performed similarly well in identifying abnormal amy
Blood-based biomarkers offer strong potential to revolutionize diagnosis, trial enrolment and treatment monitoring in Alzheimer's disease (AD). However, further advances are needed before these biomarkers can achieve wider deployment beyond selective research studies and specialty memory clinics, including the development of frameworks for optimal interpretation of biomarker profiles. We hypothesized that integrating Alzheimer's disease genetic risk score (AD-GRS) data would enhance the diagnostic value of plasma AD biomarkers by better capturing extant disease heterogeneity.
View Article and Find Full Text PDFBackground And Aims: Neurofilament light chain (NfL) is an emerging biomarker of neurodegenerative disease progression. As plasma NfL increases with age, characterization of NfL concentrations in an age-stratified cognitively unimpaired population was assessed.
Materials And Methods: EDTA-plasma samples were measured using the Simoa® NF-light™ Advantage Kit assay.
Objectives: Bovine alkaline phosphatase (BALP) mediated interference is a potential issue in the Beckman Access unconjugated estriol (uE3) assay. As the uE3 assay is a component of second trimester maternal serum screening characterizing this interference is essential for delivering accurate trisomy 18 and trisomy 21 risks.
Design And Methods: Residual serum samples (n = 517) were measured by two different lots of uE3 assay.